Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Paul Richardson, Sundar Jagannath, Mohamad Hussein, James Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William Bensinger, Ashraf Z. Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight, Kenneth C. Anderson

Blood (2009) 114 (4): 772–778.

https://doi.org/10.1182/blood-2008-12-196238

Published: 2009

Journal Articles

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Jr, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, John Crowley

Blood (2008) 112 (8): 3115–3121.

https://doi.org/10.1182/blood-2008-03-145235

Published: 2008

Journal Articles

First thalidomide clinical trial in multiple myeloma: a decade

Frits van Rhee, Madhav Dhodapkar, John D. Shaughnessy, Jr, Elias Anaissie, David Siegel, Antje Hoering, Jerome Zeldis, Bonnie Jenkins, Seema Singhal, Jayesh Mehta, John Crowley, Sundar Jagannath, Bart Barlogie

Blood (2008) 112 (4): 1035–1038.

https://doi.org/10.1182/blood-2008-02-140954

Published: 2008

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

Journal Articles

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

Jean-Luc Harousseau, Donna Weber, Meletios Dimopoulos, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, David Siegel

Blood (2007) 110 (11): 3598.

https://doi.org/10.1182/blood.V110.11.3598.3598

Published: 2007

Journal Articles

Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).

Jesus F. San Miguel, Meletios Dimopoulos, Donna Weber, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, Vincent Rajkumar

Blood (2007) 110 (11): 2712.

https://doi.org/10.1182/blood.V110.11.2712.2712

Published: 2007

Journal Articles

ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).

Asher A. Chanan-Khan, Meletios Dimopoulos, Donna Weber, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, Jesus F. San Miguel

Blood (2007) 110 (11): 2721.

https://doi.org/10.1182/blood.V110.11.2721.2721

Published: 2007

Journal Articles

Lenalidomide/Dexamethasone Improves Response and Prolongs Time to Progression, Even in Patients with IgA Multiple Myeloma: A Sub-Analysis of the MM-009/010 Studies.

Robert Foa, Donna Weber, Meletios Dimopoulos, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, Asher Alban Chanan-Khan

Blood (2007) 110 (11): 4839.

https://doi.org/10.1182/blood.V110.11.4839.4839

Published: 2007

Journal Articles

Prolonged Overall Survival with Lenalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma.

Donna Weber, Robert Knight, Christine Chen, Andrew Spencer, Zhinuan Yu, Jerome Zeldis, Marta Olesnyckyj, Meletios Dimopoulos

Blood (2007) 110 (11): 412.

https://doi.org/10.1182/blood.V110.11.412.412

Published: 2007

Journal Articles

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Edward Stadtmauer, MD, Donna Weber, MD, M. Dimopolous, MD, Andrew Belch, MD, Michel Attal, MD, Miles Prince, MD, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, MD, Robert Knight, MD

Blood (2006) 108 (11): 3552.

https://doi.org/10.1182/blood.V108.11.3552.3552

Published: 2006

Journal Articles

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Michael Wang, MD, Robert Knight, MD, Melitios Dimopoulos, MD, David Siegel, MD, S. Vincent Rajkumar, MD, Thierry Facon, MD, Raymond Alexanian, MD, Zhinuan Yu, PhD, Jerome Zeldis, MD, PhD, Marta Olesnyckyj, Donna Weber, MD

Blood (2006) 108 (11): 3553.

https://doi.org/10.1182/blood.V108.11.3553.3553

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Asher Alban Chanan-Khan, MD, Zhinuan Yu, PhD, Donna Weber, MD, Christine Chen, MD, Ruben Niesvizky, MD, Andrew Spencer, MD, Michel Attal, MD, Andrew Belch, MD, Miles Prince, MD, Marta Olesnyckyj, Robert Knight, MD, Jerome Zeldis, MD, Meletius Dimopoulos, MD

Blood (2006) 108 (11): 3554.

https://doi.org/10.1182/blood.V108.11.3554.3554

Published: 2006

Journal Articles

Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.

Donna Weber, MD, Michael Wang, M.D., Christine Chen, M.D., Andrew Belch, M.D., Edward A. Stadtmauer, M.D., Ruben Niesvisky, M.D., Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, M.D., Robert D. Knight, M.D., Meletios Dimopoulos, M.D.

Blood (2006) 108 (11): 3547.

https://doi.org/10.1182/blood.V108.11.3547.3547

Published: 2006

Journal Articles

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

Donna E. Reece, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Lisa Wang, Saima Dean, Vishal Kukreti, MD, Joseph R. Mikhael, MD, Suzanne Trudel, MD, Robert Knight, MD, Jerome Zeldis, MD

Blood (2006) 108 (11): 3548.

https://doi.org/10.1182/blood.V108.11.3548.3548

Published: 2006

Journal Articles

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

Donna E. Reece, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Lisa Wang, Saima Dean, Suzanne Trudel, MD, Joseph R. Mikhael, MD, Vishal Kukreti, MD, Robert Knight, MD, Jerome Zeldis, MD

Blood (2006) 108 (11): 3550.

https://doi.org/10.1182/blood.V108.11.3550.3550

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Donna Weber, Meletius Dimopoulos, Christine Chen, Reuben Niesvizky, Michael Wang, Andrew Belch, Michel Attal, Andrew Spencer, Miles Prince, Marta Olesnyckyj, Jerome Zeldis, Zhinuan Yu, Robert Knight

Blood (2006) 108 (11): 3551.

https://doi.org/10.1182/blood.V108.11.3551.3551

Published: 2006

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, Animesh Pardanani, MD, PhD, David P. Steensma, MD, Mark Litzow, MD, William Hogan, MD, Susan Geyer, PhD, Wenting Wu, PhD, Jerome Zeldis, MD, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 2689.

https://doi.org/10.1182/blood.V108.11.2689.2689

Published: 2006

Journal Articles

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

Antonio Palumbo, MD, Patrizia Falco, MD, Antonietta Falcone, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Nicola Giuliani, MD, Giuseppe Rossi, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Maria Teresa Ambrosini, MD, Jerome Zeldis, MD, Robert Knight, MD, Robin Foà, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2006) 108 (11): 800.

https://doi.org/10.1182/blood.V108.11.800.800

Published: 2006

Journal Articles

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Blood (2006) 108 (10): 3458–3464.

https://doi.org/10.1182/blood-2006-04-015909

Published: 2006

Journal Articles

Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Emmanuel C. Besa, MD, Vanlila Swami, MD, Paul Roda, M.D, Mary Ann Laudadio, R.N., Robert Knight, MD, Jerome Zeldis, MD

Blood (2005) 106 (11): 4908.

https://doi.org/10.1182/blood.V106.11.4908.4908

Published: 2005

NARROW

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

First thalidomide clinical trial in multiple myeloma: a decade

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).

ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).

Lenalidomide/Dexamethasone Improves Response and Prolongs Time to Progression, Even in Patients with IgA Multiple Myeloma: A Sub-Analysis of the MM-009/010 Studies.

Prolonged Overall Survival with Lenalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma.

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Reversal of Myelofibrosis in a Patient with Low Risk Myelodysplastic Syndrome on Revlimid Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only